Heartflow, Inc. · NASDAQ:HTFL

Heartflow — Corporate Update (March 2020)

12 slides from Heartflow's corporate update, March 2020

  1. Slide 1: COVID-19 Guidance and Considerations

    COVID-19 Guidance and Considerations

  2. Slide 2: COVID-19 Guidance and Considerations

    COVID-19 Guidance and Considerations • As the COVID-19 situation continues to evolve, guidance documents around elective procedures are being published daily by various entities (government bodies, professional societies, publications, etc.) • The following provides a summary of: ! Clinical implicat

  3. Slide 3: COVID-19 and Cardiovascular Disease

    COVID-19 and Cardiovascular Disease Driggin, Parikh, et al, JACC 2020 85535685 v1 2

  4. Slide 4: JACC: Some patients presenting with elevated troponins may have COVID-19 myocarditis

    JACC: Some patients presenting with elevated troponins and other signs of STEMI or ACS may actually have COVID-19 related myocarditis Myocarditis related to COVID-19 may complicate diagnosis of STEMI / ACS. Key excerpts: With severe respiratory infection and hypoxia, especially in the setting of sev

  5. Slide 5: Lancet: High Burden of Underlying CVD in COVID-19 Patients

    Lancet: High Burden of Underlying CVD in COVID-19 Patients 85535685 v1 Lancet 2020, Chen et al 4

  6. Slide 6: Advisory Board: COVID-19 Clinical Implications for CV Patients

    Advisory Board: COVID-19 Clinical Implications for CV Patients Link to Advisory Board article Cardiovascular disease is a significant comorbidity for COVID-19 85535685 v1 https://www.advisory.com/research/cardiovascular-roundtable/cardiovascular-rounds/2020/03/cv-leaders-respond-covid-19-coronavirus

  7. Slide 7: CMS recommends postponing most elective procedures

    CMS recommends postponing Tiers Action Definition Locations Examples Low acuity surgery/healthy HOPD* Carpal tunnel release most elective procedures Tier 1a Postpone surgery/procedure patient Outpatient surgery Not life-threatening ASC** Hospital with low/no COVID-19 census EGD Colonoscopy Cataracts

  8. Slide 8: SCCT: Use of CCTA during COVID-19 Pandemic

    SCCT: Use of CCTA during COVID-19 Pandemic Utilizing CCTA can reduce need for ICA, inpatient admissions and resource use Link to SCCT guidance 85535685 v1 7

  9. Slide 9: SCCT: Use of CCTA during COVID-19 Pandemic

    SCCT: Use of CCTA during COVID-19 Pandemic Data points to consider for determining elective vs. urgent patient types: • In ISCHEMIA, 5% of patients with left main disease were identified by CCTA (AHA 2019) • SCOT-HEART demonstrated 41% reduction in death and MI at 5 years with CCTA (Newby, et al. N

  10. Slide 10: ACC/SCAI: Defer PCIs for Stable Ischemic Heart Disease

    ACC/SCAI: Defer PCIs for Stable Ischemic Heart Disease ACC/SCAI recommend avoiding elective invasive procedures when possible. CCTA+FFRCT has been shown to safely defer >60% of invasive diagnostic angiograms Key Excerpts: Under any circumstance, to preserve hospital bed capacity, it would seem reaso

  11. Slide 11: COVID-19 Considerations: Role of CCTA-first Pathway

    COVID-19 Considerations: Role of CCTA-first Pathway Utilization of a CCTA-first diagnostic pathway in symptomatic patients for whom cardiac testing cannot wait can offer the following benefits: • Non-invasive with little requirement for contact between patient and providers • Highly accurate CAD dia

  12. Slide 12: 11

    11

Heartflow — Corporate Update (March 2020) on 6ix